Health Care • Biotechnology: Pharmaceutical Preparations
$30.22 ▲ +0.11
(+0.37%)
MKT CAP: $1.38B • VOL: 139.0K
52W L $7 52W H $59
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
KRSA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.1M | $2.0M | $0 |
| YoY Revenue Growth % | +3.7% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.0M | -$3.6M | -$13.0M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$3.5M | -$3.1M | -$5.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.3M | -$4.3M | -$21.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$3.3M | -$4.3M | -$21.2M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.2M | $3.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.1M | $8.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KRSA.